Jan Medina
Head of Investor Relations & VP
Good morning, everyone. Thank you for standing by, and thank you for joining our conference call this morning to discuss our recently announced effort to pursue izicopan for AAV and other renal diseases. Today’s presentation will take about 45 minutes. [Operator Instructions] Please note that today’s call is also being recorded. [Operator Instructions] As I said, we’ll be done in about 45 minutes this morning and get you on your way.
I would now like to turn the call over to Niels Riedemann, CEO and Founder of InflaRx. Niels, please go ahead.
Niels Riedemann
Co-Founder, CEO & Executive Director
Thank you, Jan. Ladies and gentlemen, good morning, and thanks for listening in. It is our pleasure to be sharing with you our recent prioritization here on the renal space, particularly in the ANCA-associated vasculitis. So may I please ask to forward to first slides. Please take note of the important notice and disclaimers. We will be making forward-looking statements. We are a public-listed company. So I appreciate your taking note.
Next slide, please. So we’re excited about our new molecule, izicopan, which is an oral inhibitor of the C5a receptor really. The C5a/C5aR pathway is a critical driver of inflammatory cascade, both angles, C5a, the ligand and its main receptor C5aR, both validated targets. From a clinical, both and the regulatory and commercial perspective also in ANCA-associated
Credit: Source link
